Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 1, 2005, Pages 97-104

  Jaglowski, Jeffrey R ^a   Zagon, Ian S ^a   Stack Jr , Brendan C ^a   Verderame, Michael F ^a   Leure duPree, Alphonse E ^a   Manning, Jeffrey D ^a   McLaughlin, Patricia J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Chemoprotection; Nude mice; Opioid growth factor; Opioid growth factor receptor; Paclitaxel

Indexed keywords

METENKEPHALIN; PACLITAXEL; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; INOCULATION; LIFESPAN; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RANDOMIZATION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; ANIMAL; ANIMAL DISEASE; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECT; HEAD AND NECK TUMOR; PATHOLOGY; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY WEIGHT; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE PROGRESSION; ENKEPHALIN, METHIONINE; HEAD AND NECK NEOPLASMS; MALE; MICE; MICE, NUDE; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 21244483812     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0929-4     Document Type: Article

References (35)

1. Arbuck SG, Cannetta R, Onetto N, Christian MC (1993) Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 20:31-39
2. Carew JF, Shah JP (1998) Advances in multimodality therapy for laryngeal cancer. CA Cancer J Clin 48:211-228
3. Carpinterio A, Peinert S, Ostertag W, Zander AR, Hossfeld DK, Kuhlcke K, Eckert HG, Baum C, Hegewisch-Becker S (2002) Generic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice. Int J Cancer 98:785-792
4. Forastiere AA, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G (1998) Final report of a phase II evaluation of paclitaxel with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82:2270-2274
5. Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J (1999) Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 86:2364-2369
6. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics. CA Cancer J Clin 54:8-29
7. Kieback DG, Dagmar-Christiane F, Engehausen DG, Sauerbrei W, Oehler MK, Tong X-W, Aguilar-Cordova E (2002) Intraperitoneal adenovirus-mediated suicide gene therapy in combination with human ovarian cancer. Cancer Gene Ther 9:478-481
8. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA (1981) Human squamous cell carcinoma. Arch Otolaryngol 107:703-710
9. Kurbacher CM, Mallmann PK (1998) Chemoprotection in anticancer therapy: the emerging role of amifostine. Anticancer Res 18:2203-2210
10. Leonard CE, Chan DC, Chou T-C, Kumar R, Bunn PA (1996) Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 56:5198-5204
11. 5]-enkephalin, and the zeta opioid receptor in head and neck squamous cell carcinoma. Laryngoscope 107:335-339
12. Leyvraz S, Ohnuma T, Lassus M, Holland JF (1985) Phase I study in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol 3:1385-1392
13. McLaughlin PJ, Levin RJ, Zagon IS (1999) Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 14:991-998
14. McLaughlin PJ, Levin RJ, Zagon IS (2000) The opioid growth factor receptor (OGFr) in human head and neck squamous cell carcinoma. Int J Mol Med 5:191-196
15. McLaughlin PJ, Levin RJ, Zagon IS (2003) Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett 199:209-217
16. McLaughlin PJ, Stack BC, Levin RJ, Fedok F, Zagon IS (2003) Defects in the OGF receptor (OGFr) in human squamous cell carcinoma of the head and neck. Cancer 97:1701-1710
17. McLaughlin PJ, Jaglowski JR, Verderame MF, Stack BC, LeureduPree AE, Zagon IS (2005) Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int J Oncol 26:809-816
18. McLaughlin PJ, Stack BC, Braine KM, Ruda JD, Zagon IS (2004) Opioid growth factor (OGF) inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. Int J Oncol 24:227-232
19. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49:33-64
20. Schantz S, Harrison LB, Forastiere AA (1997) Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 741-801
21. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565
22. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667
23. Shah JP, Lydiatt W (1995) Treatment of cancer of the head and neck. CA Cancer J Clin 45:352-368
24. Shim WSN, Teh M, Mack POP, Ge R (2001) Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. Int J Cancer 94:6-15
25. Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK (2001) Phase II study of paclitaxel, ifosafamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91:1316-1323
26. Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS (2004) Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs 15:203-209
27. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL (1998) Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18:3509-3517
28. Villena-Heinsen C, Friedrich M, Ertan AK, Farnhammer C, Schmidt W (1998) Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride. Anticancer Drugs 9:557-563
29. Vokes EE, Haraf DJ, Stenson K, Stupp R, Malone D, Levin J, Weichselbaum RR (1995) The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol 22:8-12
30. 5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin. Cell Prolif 33:63-73
31. Zagon IS, McLaughlin PJ (2003) Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 37:79-88
32. Zagon IS, Wu Y, McLaughlin PJ (1994) Opioid growth factor (OGF) inhibits DNA synthesis in mouse tongue epithelium in a circadian-rhythm-dependent manner. Am J Physiol 267:R645-R652
33. Zagon IS, Wu Y, McLaughlin PJ (1999) Opioid growth factor and organ development in rat and human embryos. Brain Res 839:313-322
34. Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ (2000) Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol 17:1053-1061
35. Zagon IS, Verderame MF, Allen SS, McLaughlin PJ (2000) Cloning, sequencing, chromosomal location, and function of a cDNA encoding the opioid growth factor receptor (OGFr) in humans. Brain Res 856:75-83